Market News AIOpen the app

Leerink Partners started following Palvella Therapeutics, predicting its stock could reach $228 per share.

OpinionRead the original at marketscreener.com
Good for PVLA

Leerink began covering Palvella with an Outperform rating and a $228-per-share target. That favorable view supports confidence, but the report gives no new company results or trial news.

PVLA · Palvella Therapeutics, Inc.

AI read · Good for PVLA

The AI's read

A favorable outside view can bring attention to Palvella and signal confidence in its prospects. The report gives no new trial results or company forecast, so the support comes from the analyst's opinion alone.

Get alerts for PVLA

Follow Palvella Therapeutics, Inc. (PVLA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PVLA
Free on the App Store and Google Play, or on the web.